Comparing ADMA Biologics (ADMA) & Applied Genetic Technologies (AGTC)

ADMA Biologics (NASDAQ:ADMA) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Volatility and Risk

ADMA Biologics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, Applied Genetic Technologies has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Insider and Institutional Ownership

53.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 48.9% of Applied Genetic Technologies shares are owned by institutional investors. 16.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 5.6% of Applied Genetic Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ADMA Biologics and Applied Genetic Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ADMA Biologics $22.76 million 11.02 -$43.75 million ($1.91) -2.83
Applied Genetic Technologies $24.19 million 4.86 -$21.30 million ($1.18) -5.50

Applied Genetic Technologies has higher revenue and earnings than ADMA Biologics. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for ADMA Biologics and Applied Genetic Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics 0 0 6 0 3.00
Applied Genetic Technologies 0 2 3 0 2.60

ADMA Biologics currently has a consensus target price of $11.58, suggesting a potential upside of 114.11%. Applied Genetic Technologies has a consensus target price of $7.00, suggesting a potential upside of 7.86%. Given ADMA Biologics’ stronger consensus rating and higher possible upside, research analysts clearly believe ADMA Biologics is more favorable than Applied Genetic Technologies.

Profitability

This table compares ADMA Biologics and Applied Genetic Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ADMA Biologics -243.42% -155.19% -55.85%
Applied Genetic Technologies -67.02% -18.97% -15.19%

Summary

ADMA Biologics beats Applied Genetic Technologies on 8 of the 14 factors compared between the two stocks.

ADMA Biologics Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit